H.R. 5260: Reduced Costs and Continued Cures Act
Before you vote › Federal bills
H.R. 5260: Reduced Costs and Continued Cures Act
117th Congress · introduced 2021-09-14 · Health · Latest: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
federal
Follow this bill, step by step
- Where it came from: introduced 2021-09-14 · official record
- Who proposed it: Rep. Peters, Scott H. [D-CA-52] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
Reduced Costs and Continued Cures Act
Plain summary
Reduced Costs and Continued Cures Act This bill establishes and alters several programs and requirements relating to the prices of prescription drugs. For example, the bill establishes and alters several requirements under Medicare and Medicaid, including requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation, capping annual out-of-pocket spending under the Medicare prescription drug benefit, and increasing the maximum rebate amount under the Medicaid Drug Rebate Program. The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics, limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
Reduced Costs and Continued Cures Act
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. Peters, Scott H. [D-CA-52] · 5 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
J. Luis Correa (D-CA), Josh Gottheimer (D-NJ)
Sponsor's campaign money: Rep. Peters, Scott H. [D-CA-52] reported raising $2.2 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Words on this page, explained (2)
- Bill
- A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).
- Rulemaking
- The process agencies use to write regulations that carry out laws passed by Congress or a legislature. Usually an agency publishes a proposed rule, takes public comments, then publishes a final rule.
Plain meanings written from linked sources. All words.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-117hr5260.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hr>
Record fed-us-cong117-hr5260 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117